Skip to main content

Smith & Nephew Updates Share Capital and Voting Rights as of 31 January 2026

Tipranks - Tipranks - Tue Feb 3, 1:06PM CST

Claim 50% Off TipRanks Premium

Smith & Nephew Snats ( (SNN) ) has shared an update.

As of 31 January 2026, Smith & Nephew plc reported a total issued share capital of 877,724,845 ordinary shares of US$0.20 each, of which 27,912,707 are held in treasury. This leaves 849,812,138 ordinary shares carrying one voting right each, a figure the company highlighted on 2 February 2026 as the key denominator for investors assessing whether they must disclose shareholdings or changes in holdings under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules, ensuring clarity for shareholders and the market on current voting rights and capital structure.

The most recent analyst rating on (SNN) stock is a Hold with a $34.91 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.

Spark’s Take on SNN Stock

According to Spark, TipRanks’ AI Analyst, SNN is a Neutral.

Smith & Nephew Snats’ strong financial performance and positive earnings call are the main drivers of its stock score. However, bearish technical indicators and a high P/E ratio temper the overall outlook. The company’s strategic initiatives, such as the share buyback, reflect confidence in its financial health, but challenges in emerging markets and tariff impacts pose risks.

To see Spark’s full report on SNN stock, click here.

More about Smith & Nephew Snats

Smith & Nephew plc is a UK-based medical technology company listed in both London and New York, focused on orthopaedics, sports medicine, ENT, and advanced wound management products for healthcare providers worldwide.

Average Trading Volume: 704,503

Technical Sentiment Signal: Strong Buy

Current Market Cap: $14.44B

For a thorough assessment of SNN stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Trending Articles

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).